A New Class of Cancer Drugs May Be Less Toxic
Late spring marks the annual meeting of the American Society of Clinical Oncology (ASCO) from which usually comes a rash of reporting about the latest advances in cancer research and treatment. This year is no different, and what’s received a lot of attention is a new class of cancer drugs known as antibody-drug conjugates that could be more effective and less toxic than current treatment options. The New York Times reports on one such experimental treatment–Trastuzumab emtansine (T-DM1)–which is now being trialled at several cancer centers around the country, including here at SCCA.
For more about ASCO, check out the site they maintain that includes all the notable news from the conference (written in English). Read the Times story about antibody-drug conjugates here.
Two Questions To Ask Before A Colonoscopy
Not all colonoscopies are created equal. What makes one colonoscopy better than another has do with the skill level of the physican performing it. NPR found two questions that will help you determine if your gastroenterologist up to the task.